Imunomodulatorni učinci radioterapije by Lidija Beketić Orešković & Martina Mikulandra
72
REVIEW Libri Oncol. 2017;45(2-3):72–77
IMMUNOMODULATORY EFFECTS OF RADIOTHERAPY
LIDIJA BEKETIĆ-OREŠKOVIĆ1,2 AND MARTINA MIKULANDRA2
1Department of Clinical Oncology, School of Medicine, 
University of Zagreb, Zagreb, Croatia 
2Department of Radiotherapy and Internal Oncology, University Hospital for Tumors, 
Sestre milosrdnice University Hospital Center, Zagreb, Croatia
Summary
It is well known that radiotherapy, as mainly locoregional treatment, has systemic eﬀ ects as well. The term abscopal 
eﬀ ect (latin: ab – away from; scopus – target) has been used to describe the regression of distant tumor metastases after 
completion of primary tumor radiation therapy. It has been shown that radiotherapy can initiate systemic antitumor im-
munologic response which includes the activation of cytotoxic T-lymphocytes via numerous complex mechanisms. Latest 
fi ndings indicate that there is an extremely complex interaction between the eﬀ ects of radiotherapy, the activation of diﬀ er-
ent signal pathways, tumor microenvironment and immunologic response. Depending on diﬀ erent tumor and host immune 
system characteristics, radiation therapy may have either immunostimulatory or immunosuppressive eﬀ ects. Several case 
reports and smaller studies have described tumor regression after concurrent application of immunotherapy and radiation 
therapy, mainly in metastatic melanoma, but also in other cancers, such as castration-resistant prostate cancer, breast cancer, 
non-small cell lung cancer, etc. Many studies researching possible immunomodulatory properties of radiotherapy, as well 
as the combination of radiotherapy and immunotherapy are currently in progress. Bett er understanding of molecular mech-
anisms of tumor immunologic regulation and the immunomodulatory eﬀ ects of radiotherapy will open possibilities of 
creating new more eﬀ ective therapeutic options in treatment of malignant diseases.
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IMUNOMODULATORNI UČINCI RADIOTERAPIJE
Sažetak
Poznato je da radioterapija, kao primarno lokoregionalno liječenje ima i svoje sistemske učinke. Radioterapijski apsko-
palni učinak (latinski: ab – od; scopus – cilj, meta), odnosi se na povlačenje udaljenih presadnica nakon provedene radiotera-
pije primarnog tumora. Pokazano je da radioterapija može potaknuti sustavni protutumorski imunosni odgovor koji 
uključuje aktivaciju citotoksičnih T-limfocita putem složenih mehanizama. Najnovija istraživanja ukazuju da postoji izuzet-
no složeno međudjelovanje zračenja, aktivacije različitih signalnih putova, tumorskog mikro okoliša i imunosnog odgovora. 
Radioterapija može djelovati imunostimulativno i imunosupresivno, ovisno o obilježjima tumora i imunološkog sustava. 
Opisana su moguća povlačenja tumora nakon istovremene primjene imunoterapije i radioterapije u metastatskom melano-
mu, kastracijski rezistentnom raku prostate, raku dojke, raku pluća nemalih stanica, itd. U tijeku su ispitivanja mogućih 
imunomodulatornih učinaka radioterapije, kao i djelovanje kombinacije radioterapije i imunoterapije. Bolje razumijevanje 
molekularnih mehanizama i radioterapijskog imunomodulatornog djelovanja otvara mogućnosti učinkovitijeg pristupa 
liječenju zloćudnih bolesti.




For many years radiotherapy has been estab-
lished as one of the most important modalities of 
cancer treatment. Whether it is performed in de-
fi nitive, neoadjuvant, adjuvant or palliative set-
ting, it is primarily a locoregional treatment, but 
systemic eﬀ ects of radiotherapy are observed as 
well. Over the past six decades, number of clinical 
cases describing regression and even eradication 
of distant metastases following radiation therapy, 
were published. The patients presented in case re-
ports diﬀ ered by age, sex and type of tumor. How-
ever, it was observed that this eﬀ ect more fre-
quently occurred in patients with immunogenic 
tumors, such as leukemias and lymphomas, while 
it seemed to be less common in solid tumors (1). 
This phenomenon of possible regression of distant 
tumor metastases after completion of radiothera-
py is known as the abscopal eﬀ ect. The name de-
rives from the Latin word ab, meaning away from 
and the Latin word scopus, which means target, 
and was fi rst introduced in 1953 by Mole (2).
Immunomodulatory eﬀ ects of radiotherapy 
and the abscopal eﬀ ect
Abscopal eﬀ ect of radiotherapy has been 
known for many years. The fi rst theory proposed 
radiation scatt ering as a possible cause of abscopal 
eﬀ ect. However, although the quantity of scat-
tered radiation is dependent on the radiation vol-
ume and intensity, it does not normally exceed 3% 
of the total dose, and cannot possibly result in any 
systemic antitumor activity (1,3,4). It is known to-
day that radiotherapy has numerous immuno-
modulatory eﬀ ects and these complex mecha-
nisms are still under investigation (5).
It has been shown that immune system can 
be aﬀ ected and modifi ed by radiation therapy on 
many levels. Radiation therapy leads to a specifi c 
type of cell death, known as the immunogenic cell 
death. The immunogenic cell death is character-
ized by the unique processes that occur on the mo-
lecular level within the cell. This includes the re-
lease of ATP, the upregulation of costimulatory 
molecules, the translocation of calreticulin (a pro-
tein that plays an important role in cancer cell ad-
hesion) on cell surface, as well as the increase in 
the release of DAMP (damage-associated molecu-
lar patt erns) molecules. DAMP activate dendritic 
cells (DCs) of the immune system in a way similar 
to the antigens of pathogenic origin, which ulti-
mately leads to the activation of cytotoxic T-lym-
phocytes (6–8). The best known DAMP molecule 
is HMBG-1 (high-mobility group box 1), an ago-
nist of toll-like receptor 4 (9,10). Toll-like receptors 
are a group of transmembrane proteins which are 
expressed in many cells, including antigen-pre-
senting cells, where they play a key role in initia-
tion of innate immune response via recognition of 
PAMP (pathogen-associated molecular patt erns) 
and DAMP molecules (11,12), and are currently 
the focus of numerous studies in the fi eld of im-
munotherapy.
It has been shown that radiation therapy re-
sults in increased expression of Fas molecule (a 
trigger of programmed cell death) and the major 
histocompatibility complex - MHC I (8,13,14), 
which is responsible for antigen presentation to 
cytotoxic CD8+ lymphocytes. It appears that radia-
tion therapy can also activate CD8+ lymphocytes 
through the induction of type I interferons (15,16). 
Several studies on animal models have confi rmed 
that the activation of CD8+ lymphocytes is a key 
marker of radiosensitivity of the primary tumor 
(17–20), and is crucial for the development of ab-
scopal eﬀ ect (21).
The mechanisms of combination of radio-
therapy and immunotherapy have been studied 
for several years. Golden et al. showed that the ad-
dition of immunotherapy to standard radiothera-
py treatment consistently leads to abscopal eﬀ ect 
in patients with metastatic solid tumors (22). The 
study included 41 patients with stable or progres-
sive malignant disease and at least three measur-
able tumor lesions. Patients were diagnosed with 
diﬀ erent types of cancer, although a slight major-
ity had non-small cell lung and breast cancer. In 
addition to standard treatment regimen, patients 
received subcutaneous injections of granulocyte-
macrophage colonies stimulating factor (GM-
CSF), and radiation to one of the measurable le-
sions at a dose of 35 Gy in 10 fractions (3.5 Gy per 
fraction). Evaluation of therapeutic response was 
performed using clinical exam and CT scans 7-8 
weeks after completion of radiation therapy. The 
abscopal eﬀ ect was defi ned by 30% reduction in 
size of any of non-irradiated lesions. The results 
showed that abscopal eﬀ ect occurred in 27% of 
subjects. Also, patients who developed abscopal 
eﬀ ect had longer overall survival compared to the 
others (21 months vs. 8 months).
Lib Oncol. 2017;45(2-3):72–77
74
Several case reports and smaller studies have 
described tumor regression after concurrent ap-
plication of immunotherapy and radiation thera-
py, mainly in metastatic melanoma, but also in 
other cancers, such as castration-resistant prostate 
cancer, breast cancer, non-small cell lung cancer, 
etc. (19-24).
Latest fi ndings indicate that there is an ex-
tremely complex interaction between the eﬀ ects of 
radiotherapy, the activation of diﬀ erent signal 
pathways, tumor microenvironment and immu-
nologic response. Depending on diﬀ erent tumor 
and host immune system characteristics, radiation 
may have either immunostimulatory or immuno-
suppressive eﬀ ects. It seems that radiation thera-
py under certain conditions can aid the tumor to 
evade the immune response. Radiation therapy 
can upregulate TGF-β (transforming growth fac-
tor beta), the known mediator of tumor invasive-
ness and the epithelial-mesenchymal transition 
(23), the recruitment of T-regulatory lymphocytes 
(Tregs) and the polarization of M2 macrophages 
(24). It has been shown that radiation therapy can 
lead to the upregulation of some of the receptors 
expressed on the surface of tumor cells that have 
inhibitory eﬀ ect on T-lymphocytes. These are 
CTLA-4 (cytotoxic T lymphocyte antigen-4), PD-1 
(programmed cell death protein 1) and PD-L1 
(programmed death-ligand 1) /PD-1 (1).
Radiotherapy and immune checkpoint 
inhibitors
The knowledge of the mechanisms of tumor 
immune tolerance led to the development of spe-
cifi c immunomodulators, checkpoint inhibitors, 
such as ipilimumab inhibitor of CTLA-4 (cytotoxic 
T lymphocyte antigen-4)), pembrolizumab, nivo-
lumab, PD-1 (programmed cell death protein 1) 
and atezolizumab, inhibitor of PD-L1 (pro-
grammed cell death protein 1 ligand). While radi-
ation therapy evidently can facilitate antitumor 
immune responses, the immunosuppressive ef-
fects of radiotherapy are also known, mainly by 
upregulating of the expression of PD-L1 (19).
Many studies researching possible immuno-
modulatory properties of radiotherapy, as well as 
the combination of radiotherapy and immuno-
therapy are currently in progress (for example ra-
diotherapy with addition of checkpoint inhibi-
tors such as anti CTLA-4, anti PD-1 (programmed 
cell death protein 1), anti PDL1/L2, or with addi-
tion of TGFβ (transforming growth factor beta) 
antagonists or TLR (toll-like receptor) agonists 
(22-24).
It has been shown that the eﬃ  cacy of stereo-
tactic radiotherapy was higher in PD-L1 knockout 
mice, as well as in mice treated with anti-PD-L1 
(25). Also, the combination of anti-PD-L1 and ste-
reotactic radiotherapy showed eﬃ  cacy in mice 
with intracranial glioma (26). The investigators 
who studied the eﬃ  cacy of combination of anti-
CTLA-4 and radiation therapy in mouse model of 
metastatic breast cancer found tumor shrinkage 
and the inhibition of lung metastases in mice that 
were treated with combined regimen, with signifi -
cantly prolonged overall survival (20). On the ba-
sis of the promising results from preclinical stud-
ies and some case reports, several small clinical 
trials (mainly phase I and II) were conducted. 
Prompted by previously published case report of 
a patient with metastatic melanoma who, after 
treatment with combination of ipilimumab and 
palliative radiotherapy (total dose of 28.5 Gy in 3 
fractions) had achieved regression of melanoma 
lesions and stabilization of disease (27), Hiniker et 
al. treated a patient with asymptomatic metastatic 
melanoma with combination of ipilimumab and 
radiotherapy (total dose 54 Gy in 3 fractions). The 
treatment resulted in complete regression of pri-
mary and metastatic lesions (28). This pointed to 
the connection between the total dose of radiation 
therapy and the observed abscopal eﬀ ect. The 
combination of ipilimumab and radiotherapy was 
also studied in patients with castration-resistant 
prostate cancer. Patients received ipilimumab 
concurrently with palliative bone radiotherapy. 
Clinical response was observed in 25% of patients 
(29). In the phase I study that examined the eﬀ ect 
of the combination of stereotactic radiotherapy 
and interleukin-2 in patients with metastatic mel-
anoma and renal cell carcinoma, 8 of 12 patients 
had clinical response. Also, patients who respond-
ed to the therapy had a higher number of CD4+ 
lymphocytes (30).
Victor et al. conducted a clinical study of 
combination regimen of ipilimumab plus radio-
therapy in 22 patients with advanced melanoma, 
and later, retested the results on mouse model 
(31). In this clinical trial, a single lesion was treat-
ed with stereotactic radiotherapy (6-8Gy/2-3 frac-
tions). Three to fi ve days after the completion of 
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radiotherapy, the patients were given 4 cycles of 
ipilimumab. The evaluation of results was per-
formed using RECIST criteria, and only non-irra-
diated lesions were assessed. Partial response was 
observed in 18% of the patients, another 18% had 
stable disease, while the rest of the patients had 
disease progression. The investigators repeated 
the test using mouse model, and, while gett ing 
bett er results in a form of tumor regression, they 
still found that some mice were resistant to treat-
ment (31). They conducted further studies on the 
selected mice and found that after the completion 
of combined radiotherapy plus immunotherapy, 
the resistant tumors had lower CD8+ CD4+ to Treg 
ratio in comparison to sensitive tumors. Further 
investigation showed that combination of anti-
CTLA-4, anti-PD-L1 and radiation therapy in-
creased CD8+ to Treg ratio, working in favor of 
antitumor immunity over the evasion of immune 
response. Also, it was shown that the tumors that 
were resistant to combination therapy had upreg-
ulated PD-L1. Testing this theory, authors con-
ducted the same therapy in mice with PD-L1 
knockout melanoma cells and observed the re-
stored response. By treating mice with resistant 
melanomas with combination of anti-PD-L1, anti-
CTLA-4 and radiation, the authors achieved the 
improved response. Similar results were also ob-
served in mouse models of breast and pancreatic 
cancer. However, it is important to mention that 
the complete tumor response was not observed in 
all treated mice, meaning that the upregulation of 
PD-L1 is not only mechanism of resistance to com-
bined RT and anti-CTLA-4 therapy (31,32). It seems 
that a number of lymphocytes could be a predic-
tor of abscopal eﬀ ect in patients treated with the 
combination of ipilimumab and radiotherapy (33).
However, the total dose of radiation therapy 
and the fractionation of the dose for individual tu-
mors has not yet been defi ned. Based on the lite-
rature, Sharabi et al. recommended hypofraction-
ated regimen (5-20 Gy per fraction) (10), but 
 defi nitive guidelines require further studies. Fur-
thermore, Dovedi et al. found that the concurrent 
administration of immunotherapy with radiation 
therapy seemed to be more eﬀ ective than sequen-
tial application of the same therapy (19).
Further research is needed to determine the 
best modality treatment of radiotherapy and im-
munotherapy combination, as well as to defi ne the 
subgroup of patients who would benefi t the most 
of this combined therapy.
Toxicity of immune checkpoint inhibitors 
and combination regimens
The studies have been shown that the combi-
nation of radiotherapy and immunotherapy may 
lead to increased treatment toxicities. The immune 
checkpoint inhibitors are known to increase the 
secretion of cytokines, which results in toxicity. 
The adverse eﬀ ects of immunotherapy range from 
mild (which are most common) to severe, and 
even potentially lethal (34,35). For example, skin 
rash, hypophysitis, colitis and diarrhea are known 
adverse eﬀ ects of CTLA-4 blockade (ipilimumab), 
while pneumonitis may occur as a side eﬀ ect of 
PD-L1 blockade (1,36). The combination of radio-
therapy and immunotherapy may lead to in-
creased toxicities. For example, the risks of severe 
adverse eﬀ ects in form of pneumonitis, dyspnea 
or cough, in patients who receive anti-PD-L1 and 
anti-CTLA-4 ranges between 2 and 4% (14). The 
risk of the radiation induced pneumonitis as an 
adverse eﬀ ect of irradiation of the lung is reason-
able to consider when combining these two treat-
ment modalities. However, the improvement of 
radiation techniques that enable to minimize the 
treatment fi eld (which leads to the reduction of 
the radiation induced toxicity) brings confi dence 
in the possibility of using the combination treat-
ment without the fear of severe adverse eﬀ ects. 
Based on his, there are several ongoing clinical tri-
als which are addressing this problem by investi-
gating the safety and tolerability of combination 
of immunotherapy and radiation therapy.
CONCLUSION
Many studies researching possible immuno-
modulatory properties of radiotherapy, as well as 
the combination of radiotherapy and immunother-
apy are currently in progress. Although number of 
preclinical studies, case reports and small clinical 
trials suggest therapeutic benefi ts, further research 
is needed to determine the safety and eﬃ  cacy of 
this combined treatment. Bett er understanding of 
molecular mechanisms of tumor immunologic reg-
ulation and the immunomodulatory eﬀ ects of ra-
diation therapy will open the possibilities of creat-
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